Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma
Lymphomas are hematological malignancies, which are divided into non-Hodgkin lymphoma and
 Hodgkin lymphoma. Non hodgkin lymphoma is a lymphoma-derived malignancy that makes up about
 90% of all malignant lymphoma. According to its origin, non hodgkin lymphoma is classified
 into B-cell non hodgkin lymphoma and T-cell non hodgkin lymphoma. The most common types are
 follicular lymphoma, and diffuse large B-cell lymphoma. Lymphomas are types of cancer that
 develops from lymphocytes, a type of white blood cell. Diagnosis is by examination of a bone
 marrow or lymph node biopsy. Non hodgkin lymphoma mortality has increased in recent years and
 has become the seventh most frequently occurring cancer.
Biomarkers are defined as objective indicators of biological processes, pathogenic processes,
 or pharmacological response to a therapeutic intervention. Diagnostic biomarkers which are
 type of biomarkers, identify the presence of disease, differentiate normal from malignant,
 distinguish different diagnoses or progression stages.

 Micro ribosomal nucleic acids have been demonstrated to possess biomarker potentiality in
 multiple diseases, both individually and when combined in signature profiles. Micro ribosomal
 nucleic acids are short single-stranded noncoding ribosomal nucleic acids of 20-22
 nucleotides that function to regulate gene expression at the posttranscriptional level. They
 play fundamental roles in the regulation of cellular proliferation, differentiation, and
 apoptosis. Dysregulation of micro ribosomal nucleic acid is a unique feature of cancers
 including lymphomas . Information about the functional role of micro ribosomal nucleic acid
 dysregulation in lymphomas is increasing day by day.

 The present study focuses on the micro ribosomal nucleic acid 155 since this molecule
 represents a typical multifunctional micro ribosomal nucleic acid. To date, increased
 evidence points out that micro ribosomal nucleic acid 155 is involved in numerous biological
 processes including haematopoiesis, inflammation and immunity. Deregulation of micro
 ribosomal nucleic acid 155 has been found to be associated with different kinds of cancer,
 cardiovascular diseases and viral infections. Since investigation on the functional activity
 of micro ribosomal nucleic acid 155 started a few years ago, it is reasonable to predict that
 many other functions will be uncovered in the near future.

 Micro ribosomal nucleic acid 155 maps within and is processed from an exon of a noncoding
 ribosomal nucleic acid transcribed from the B-cell Integration Cluster located on chromosome
 21.

 Micro ribosomal nucleic acid 155 is an oncological micro ribosomal nucleic acid with a
 crucial role in tumor initiation and development of several B-cell malignancies. Micro
 ribosomal nucleic acid 155 was upregulated in several malignancies compared to nonmalignant
 controls and overexpression of micro ribosomal nucleic acid 155 was further associated with
 poor prognosis. Elevated expression of micro ribosomal nucleic acid 155 shows potentiality as
 a diagnostic and prognostic biomarker in diffuse large B-cell lymphoma and chronic
 lymphocytic leukemia. Additionally, in vitro and in vivo studies suggest micro ribosomal
 nucleic acid 155 as an efficient therapeutic target, supporting its oncogenic function. The
 use of inhibiting anti-micro ribosomal nucleic acid structures indicates promising potential
 as novel anticancer therapeutics.

 The search for non-invasive tools for the diagnosis and management of cancer has long been a
 goal of cancer research that has led to great interest in the field of circulating nucleic
 acids in plasma and serum.
Inclusion Criteria:

 -  Non hodgkin lymphoma patients of any age or sex.

 -  healthy volunteers within the same range of age.

 Exclusion Criteria:

 -  patients with any other haematological malignancy.